These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 2519875

  • 1. Noble PRST-1 Ca prostate adenocarcinoma study on noble rats: preliminary study on new androgen sensitive tumor.
    Wientjes G, Smith J, Miller R, Badalament RA, Drago JR.
    In Vivo; 1989; 3(5):335-7. PubMed ID: 2519875
    [Abstract] [Full Text] [Related]

  • 2. Testosterone-mediated increase in 5 alpha-dihydrotestosterone content, nuclear androgen receptor levels, and cell division in an androgen-independent prostate carcinoma of Noble rats.
    Ho SM, Leav I, Damassa D, Kwan PW, Merk FB, Seto HS.
    Cancer Res; 1988 Feb 01; 48(3):609-14. PubMed ID: 3257169
    [Abstract] [Full Text] [Related]

  • 3. The Nb rat prostatic adenocarcinoma model system.
    Drago JR, Goldman LB, Maurer RE.
    Prog Clin Biol Res; 1980 Feb 01; 37():265-91. PubMed ID: 7384086
    [Abstract] [Full Text] [Related]

  • 4. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma.
    Drago JR, Weed P, Fralisch A.
    Anticancer Res; 1984 Feb 01; 4(3):171-2. PubMed ID: 6540544
    [Abstract] [Full Text] [Related]

  • 5. Retardation of prostate tumor progression in the Noble rat by 4-methyl-4-aza-steroidal inhibitors of 5 alpha-reductase.
    Kadohama N, Wakisaka M, Kim U, Karr JP, Murphy GP, Sandberg AA.
    J Natl Cancer Inst; 1985 Feb 01; 74(2):475-86. PubMed ID: 3856054
    [Abstract] [Full Text] [Related]

  • 6. Growth inhibition by diethylstilbestrol and relapse of the Noble rat prostatic tumor.
    Wakisaka M, Drury RE, Kadohama N.
    Hinyokika Kiyo; 1988 Jan 01; 34(1):107-15. PubMed ID: 3376790
    [Abstract] [Full Text] [Related]

  • 7. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
    Chang CJ, Ghosh PK, Hu YF, Brueggemeier RW, Lin YC.
    Res Commun Chem Pathol Pharmacol; 1993 Mar 01; 79(3):293-312. PubMed ID: 8480076
    [Abstract] [Full Text] [Related]

  • 8. The Nb rat: prostatic adenocarcinoma model.
    Drago JR, Ikeda RM, Maurer RE, Goldman LB, Tesluk H.
    Invest Urol; 1979 Mar 01; 16(5):353-9. PubMed ID: 429131
    [Abstract] [Full Text] [Related]

  • 9. Nb rat prostate adenocarcinoma model: metastasis.
    Drago JR, Curley RM, Sipio JC.
    Anticancer Res; 1985 Mar 01; 5(2):193-6. PubMed ID: 2581494
    [Abstract] [Full Text] [Related]

  • 10. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
    Humphries JE, Isaacs JT.
    Cancer Res; 1982 Aug 01; 42(8):3148-56. PubMed ID: 7093958
    [Abstract] [Full Text] [Related]

  • 11. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 12. Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of noble rats.
    Yu M, Leav BA, Leav I, Merk FB, Wolfe HJ, Ho SM.
    Lab Invest; 1993 Jan 15; 68(1):33-44. PubMed ID: 8423674
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
    Ellis WJ, Isaacs JT.
    Cancer Res; 1985 Dec 15; 45(12 Pt 1):6041-50. PubMed ID: 4063963
    [Abstract] [Full Text] [Related]

  • 14. Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma.
    Omarbasha B, Fair WR, Heston WD.
    Cancer Res; 1989 Jun 01; 49(11):3045-9. PubMed ID: 2720665
    [Abstract] [Full Text] [Related]

  • 15. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor.
    Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL.
    Cancer Res; 1993 Oct 15; 53(20):4855-9. PubMed ID: 8402673
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar 15; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 17. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion.
    English HF, Kloszewski ED, Valentine EG, Santen RJ.
    Cancer Res; 1986 Feb 15; 46(2):839-44. PubMed ID: 3940646
    [Abstract] [Full Text] [Related]

  • 18. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Tombal B.
    Eur Urol; 2009 Feb 15; 55(2):321. PubMed ID: 18838209
    [No Abstract] [Full Text] [Related]

  • 19. A rat prostatic adenocarcinoma as a model for the human disease.
    Müntzing J, Kirdani RY, Murphy GP, Sandberg AA.
    Invest Urol; 1979 Jul 15; 17(1):37-41. PubMed ID: 447485
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.